Etoposide
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1983
- First approval year
- 1983
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Etoposide
- Molecular weight
- 588.56
- Structure (SMILES)
- COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
- etoposide
- Etoposide
- toposar
- Toposar
- vepesid
- Vepesid
- 4 demethylepipodophyllotoxin 9 4 6 o r ethylidene beta d glucopyranoside
- 4'-DEMETHYLEPIPODOPHYLLOTOXIN 9-(4,6-O-(R)-ETHYLIDENE-.BETA.-D-GLUCOPYRANOSIDE)
- avopef
- AVOPEF
- etoposide
- Etoposide
- ETOPOSIDE [EP IMPURITY]
- ETOPOSIDE [EP MONOGRAPH]
- ETOPOSIDE [HSDB]
- ETOPOSIDE [IARC]
- etoposide [INN]
- ETOPOSIDE [JAN]
- ETOPOSIDE [MART.]
- ETOPOSIDE [MI]
- ETOPOSIDE [ORANGE BOOK]
- ETOPOSIDE [USAN]
- ETOPOSIDE [USP IMPURITY]
- ETOPOSIDE [USP MONOGRAPH]
- ETOPOSIDE [USP-RS]
- ETOPOSIDE [VANDF]
- Etoposide [WHO-DD]
- ETOPOSIDE [WHO-IP]
- etoposide ep impurity
- etoposide ep monograph
- etoposide hsdb
And 29 more, listed on the interactive page.
- ATC classification codes
- L01CB01
Sources for recorded values
- CAS registry numbers
- 33419-42-0
- ChEMBL ID
- CHEMBL44657
- InChIKey
- VJJPUSNTGOMMGY-MRVIYFEKSA-N
- PubChem compound IDs
- 36462
- FDA ingredient codes (UNII)
- 6PLQ3CP4P3
- 4179
- 24614
- Applicant
- CORDEN PHARMA
- Approval date
- 10 Nov 1983
- Application number
- NDA018768
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- United States (FDA)
- Approved
- Pharmacology name
- etoposide
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- DNA topoisomerase II alpha
- Gene symbol
- TOP2A
- Protein identifier
- P11388
- Median affinity
- 7.3
- Affinity units
- pIC50
- Primary target
- Yes
- Mechanism
- DNA topoisomerase II inhibitor
- Action type
- Inhibitor
- Target
- DNA topoisomerase II
- Protein identifier
- P11388
- Mechanism
- DNA topoisomerase II inhibitor
- Action type
- Inhibitor
- Target
- DNA topoisomerase II
- Protein identifier
- Q02880
Open Targets mechanisms
- Mechanism
- DNA topoisomerase II inhibitor
- Action type
- Inhibitor
- Target
- DNA topoisomerase II
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- TOP2A
- Protein identifier
- P11388
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000094
- Subject identifier
- D015456
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Sarcoma, Ewing
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000174
- Subject identifier
- D012512
- Condition
- HIV Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Hodgkin Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Lymphoma, B-Cell, Marginal Zone
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000191
- Subject identifier
- D018442
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Neoplasms, Plasma Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000200
- Subject identifier
- D054219
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000209
- Subject identifier
- D015456
- Condition
- Lymphoma, T-Cell, Peripheral
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000211
- Subject identifier
- D016411
- Condition
- Leukemia, Erythroblastic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000218
- Subject identifier
- D004915
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Leukemia, Monocytic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000221
- Subject identifier
- D007948
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Leukemia, Myelomonocytic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000223
- Subject identifier
- D015479
- Condition
- Rhabdomyosarcoma, Alveolar
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000248
- Subject identifier
- D018232
- Condition
- Astrocytoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000272
- Subject identifier
- D001254
- Condition
- Burkitt Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000309
- Subject identifier
- D002051
- Condition
- Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000339
- Subject identifier
- D015464
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Rhabdomyosarcoma, Embryonal
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000437
- Subject identifier
- D018233
- Condition
- Ganglioneuroblastoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000502
- Subject identifier
- D018305
And 122 more, listed on the interactive page.
- Condition identifier
- EFO_0000174
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000180
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000183
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000198
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000211
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000220
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000222
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000621
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000637
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000702
- Condition identifier
- EFO_0000708
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002626
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002939
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003833
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003929
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004251
- Highest recorded phase
- 2
And 243 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- gastrointestinal toxicity
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Warning
- Black Box Warning
- Effect
- nephrotoxicity
- Warning
- Black Box Warning
- Effect
- gastrointestinal toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- nephrotoxicity
- Country
- United States
- Event
- acute myeloid leukaemia
- Reports
- 363
- Reporting signal score
- 751.254
- Event
- anaemia
- Reports
- 1,057
- Reporting signal score
- 453.718
- Event
- bone marrow failure
- Reports
- 642
- Reporting signal score
- 1,063.04
- Event
- diffuse large b-cell lymphoma recurrent
- Reports
- 123
- Reporting signal score
- 323.239
- Event
- disease progression
- Reports
- 698
- Reporting signal score
- 507.394
- Event
- disease recurrence
- Reports
- 274
- Reporting signal score
- 284.396
- Event
- febrile bone marrow aplasia
- Reports
- 183
- Reporting signal score
- 357.027
- Event
- febrile neutropenia
- Reports
- 2,929
- Reporting signal score
- 6,612.05
- Event
- haematotoxicity
- Reports
- 386
- Reporting signal score
- 798.976
- Event
- injection site pain
- Reports
- 1
- Reporting signal score
- 315.515
- Event
- leukopenia
- Reports
- 596
- Reporting signal score
- 535.205
- Event
- malignant neoplasm progression
- Reports
- 516
- Reporting signal score
- 405.616
- Event
- mucosal inflammation
- Reports
- 938
- Reporting signal score
- 1,765.35
- Event
- myelodysplastic syndrome
- Reports
- 432
- Reporting signal score
- 839.544
- Event
- myelosuppression
- Reports
- 304
- Reporting signal score
- 515.676
- Event
- nephropathy toxic
- Reports
- 241
- Reporting signal score
- 339.594
- Event
- neutropenia
- Reports
- 1,839
- Reporting signal score
- 2,021.84
- Event
- neutropenic sepsis
- Reports
- 216
- Reporting signal score
- 408.703
- Event
- ovarian failure
- Reports
- 106
- Reporting signal score
- 346.321
- Event
- pancytopenia
- Reports
- 1,065
- Reporting signal score
- 1,535.18
- Event
- posterior reversible encephalopathy syndrome
- Reports
- 223
- Reporting signal score
- 313.588
- Event
- pyrexia
- Reports
- 1,257
- Reporting signal score
- 348.24
- Event
- second primary malignancy
- Reports
- 222
- Reporting signal score
- 397.225
- Event
- sepsis
- Reports
- 718
- Reporting signal score
- 667.784
- Event
- septic shock
- Reports
- 277
- Reporting signal score
- 308.087
And 3 more, listed on the interactive page.
- NCT00000660
- NCT00001339
- NCT00304070
- NCT03583710
- NCT03723941
- NCT05913427
- NCT00002461
- NCT00002471
- NCT00002481
- NCT00002488
- NCT00002494
- NCT00002510
- NCT00002521
- NCT00002522
- NCT00002552
- NCT00002557
- NCT00002565
- NCT00002590
- NCT00002657
- NCT00002691
- NCT00002697
- NCT00002714
- NCT00002715
- NCT00002757
- NCT00002766
And 998 more, listed on the interactive page.
- Dose
- 50 mg/m2 to 100 mg/m2 or 35 mg/m2 or 37 mg/m2 to 75 mg/m2 or 26 mg/m2 or 75 mg/m2
- Route
- Intravenous
- How often
- Every 3 to 4 weeks
- Administer diluted AVOPEF over 30 to 60 minutes
- Do not administer AVOPEF by rapid intravenous injection
- Hydrogen bond acceptors
- 13
- Hydrogen bond donors
- 3
- Polar surface area
- 160.83
- Calculated partition coefficient (ALogP)
- 1.34
- Calculated partition coefficient (XLogP)
- 0.6
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 5
- Heavy atoms
- 42
- Molecular formula
- C29H32O13
- Monoisotopic mass
- 588.18429107
- Natural product
- Yes
- 0143-9376
- 0143-9510
- 0143-9511
- 0143-9512
- 0378-3266
- 16729-114
- 63323-104
- 68001-265
- 68001-681
- 68001-682
- 68001-683
- 71288-175
- 71288-176
- 71288-177
- 83270-451
- 83831-144
- 83831-145
- 69238-2811
- Recorded assays
- 8,930
- Active assays
- 2,095
- Confirmatory
- Other
- Screening
- Summary
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
These details could not be displayed.
Related records
Trials (1,403)
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma
- 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
- A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
- A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma
- A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
- A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
- A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
- A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL
- A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
- A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.
- A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
- A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)
- A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
- A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
- A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
Approved for (6)
- Cancer
- Lung cancer
- Lung neoplasm
- Neoplasm
- Small cell carcinoma
- Small cell lung carcinoma
In development for (250)
- Acquired polycythemia vera Phase 2
- Acute basophilic leukemia Phase 3
- Acute erythroid leukemia Phase 3
- Acute leukemia Phase 2
- Acute leukemia of ambiguous lineage Phase 2
- Acute lymphoblastic leukemia Phase 3
- Acute megakaryoblastic leukemia Phase 3
- Acute monocytic leukemia Phase 3
- Acute myeloblastic leukemia with maturation Phase 3
- Acute myeloblastic leukemia without maturation Phase 3
- Acute myeloid leukemia Phase 3
- Acute myeloid leukemia by FAB classification Phase 3
- Acute myelomonocytic leukemia M4 Phase 3
- Acute promyelocytic leukemia Phase 3
- Adenocarcinoma Phase 2
- Adrenal cortex carcinoma Phase 3
- Adult T-cell leukemia/lymphoma Phase 3
- AIDS Phase 2
- Alveolar rhabdomyosarcoma Phase 2
- Amyloidosis Phase 2
Other linked conditions (8)
- Chediak-Higashi syndrome
- Low grade glioma
- Ovarian germ cell tumor
- Reticulum cell sarcoma
- Retroperitoneal germ cell neoplasm
- Severe combined immunodeficiency
- Wiskott-Aldrich syndrome
- X-linked lymphoproliferative syndrome